Clinical Trial Update: Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating whether siltuximab can reduce symptom burden after autologous stem cell transplantation in patients with multiple myeloma an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis
• Multiple Myeloma

Drugs mentioned

• Siltuximab (siltuximab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma, AL Amyloidosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING